![]() Furthermore, even after the complete excision of localized or locoregional disease via surgical intervention, 30%–55% of patients who undergo resection will eventually experience the development of metastatic disease ( Uramoto and Tanaka, 2014).įor a considerable period of time, platinum-based adjuvant chemotherapy has been widely adopted as the standard treatment for individuals with resectable stage II–IIIA disease. However, exclusive reliance on surgical resection may not lead to complete cure in a substantial number of early-stage NSCLC patients, due to the escalating probability of disease relapse concurrent with disease progression. Only 25%–30% of newly diagnosed NSCLC patients have a disease, which could be considered resectable, while the majority are diagnosed at an advanced stage, either metastatic or locally advanced ( Le Chevalier, 2010). ![]() ![]() About 85% of lung cancer cases are classified as non-small cell lung cancer (NSCLC) ( de Groot et al., 2018). In the United States, there are an estimated annual incidence of 235,760 cases and 131,880 deaths associated with this condition ( Siegel et al., 2022). Lung cancer is the leading cause of mortality among all types of cancers globally. payer at a WTP threshold of $150,000 per QALY. Probabilistic sensitivity analysis showed that osimertinib exhibited a 0% chance of being considered cost-effective for patients using a WTP threshold $150,000/QALY.Ĭonclusion: In our model, osimertinib was unlikely to be cost-effective compared to placebo for stage IB to IIIA, EGFR-mutated, completely resected NSCLC patients from the perspective of a U.S. The results of the univariate sensitivity analysis indicated that the utility of disease-free survival (DFS), cost of osimertinib, and discount rate had the greatest impact on the outcomes. Results: Osimertinib produced additional 1.59 QALYs with additional costs of $492,710 compared to placebo, giving rise to ICERs of $309,962.66/QALY. Both univariate and probabilistic sensitivity analyses were carried out to explore the robustness of the model. Quality-adjusted life-years (QALYs), lifetime costs, and incremental cost-effectiveness ratio (ICER) were calculated with a willingness-to-pay (WTP) threshold of $150,000 per QALY. Methods: Based on the results obtained from the ADAURA trial, a Markov model with three-state was employed to simulate patients who were administered either osimertinib or placebo until disease recurrence or completion of the study period (3 years). We conduct a cost-effectiveness analysis comparing the use of adjuvant osimertinib to placebo in patients with stage IB to IIIA, EGFR-mutated, resected NSCLC. 3The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin, Chinaīackground: In the double-blind phase III ADAURA randomized clinical trial, adjuvant osimertinib showed a substantial overall survival benefit in patients with stage IB to IIIA, EGFR-mutated, completely resected non-small cell lung cancer (NSCLC).1 People’s Hospital, Jining, Shandong, China 1Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin, China.Gengwei Huo 1 † Ying Song 2 † Wenjie Liu 1 † Xuchen Cao 3* Peng Chen 1*
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |